Identification
- Summary
Hemin is an iron-containing porphyrin injection used for the relief of recurrent attacks of acute intermittent porphyria (AIP) associated with the menstrual cycle when carbohydrate therapy is not effective.
- Brand Names
- Panhematin
- Generic Name
- Hemin
- DrugBank Accession Number
- DB03404
- Background
Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Protein Based Therapies
Blood factors - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- chloro(protoporphyrinato)iron(III)
- Hämin
- Hemina
- hémine
- protohemin
Pharmacology
- Indication
Used in the management of porphyria attacks, particularly in acute intermittent porphyria.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab Hemin may increase the anticoagulant activities of Abciximab. Acenocoumarol Hemin may increase the anticoagulant activities of Acenocoumarol. Alteplase Hemin may increase the anticoagulant activities of Alteplase. Ancrod Hemin may increase the anticoagulant activities of Ancrod. Anistreplase Hemin may increase the anticoagulant activities of Anistreplase. Antithrombin Alfa Hemin may increase the anticoagulant activities of Antithrombin Alfa. Antithrombin III human Hemin may increase the anticoagulant activities of Antithrombin III human. Apixaban Hemin may increase the anticoagulant activities of Apixaban. Ardeparin Hemin may increase the anticoagulant activities of Ardeparin. Argatroban Hemin may increase the anticoagulant activities of Argatroban. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Panhematin Injection, powder, lyophilized, for solution 7 mg/1mL Intravenous Lundbeck Inc. 1983-07-20 2013-07-18 US 
Panhematin Powder, for solution 7 mg/1mL Intravenous RECORDATI RARE DISEASES, INC. 1983-07-20 Not applicable US Panhematin Powder, for solution 268 mg / vial Intravenous Recordati Rare Diseases Canada Inc 2018-12-05 Not applicable Canada 
Panhematin Injection, powder, lyophilized, for solution 7 mg/1mL Intravenous Recordati Rare Diseases Inc 1983-07-20 2020-01-24 US
Categories
- ATC Codes
- B06AB01 — Hemin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 743LRP9S7N
- CAS number
- 16009-13-5
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000887
- KEGG Compound
- C06767
- PubChem Substance
- 46504761
- ChemSpider
- 401223
- 5175
- ChEBI
- 50385
- RxList
- RxList Drug Page
- Wikipedia
- Hemin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Prevention Graft Failure / Ischemia Reperfusion Injury 1 2 Completed Treatment Acute Porphyria 1 2 Completed Treatment Diabetes Mellitus / Gastroparesis 1 2 Completed Treatment Myocardial Ischemia 1 2 Completed Treatment Post ERCP Acute Pancreatitis 1 2 Recruiting Prevention Acute Intermittent Porphyria (AIP) / Hereditary Coproporphyria (HCP) / Variegate Porphyria 1 2 Terminated Treatment Myelodysplastic Syndrome 1 2 Unknown Status Not Available Acute Kidney Injury (AKI) 1 1 Completed Not Available Healthy Subjects (HS) 1 Not Available Active Not Recruiting Not Available Acute Intermittent Porphyria (AIP) / Hereditary Coproporphyria (HCP) / Variegate Porphyria 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Parenteral 313 mg Injection, solution, concentrate Intravenous 25 MG/ML Injection, solution, concentrate Intravenous Solution, concentrate Intravenous 25 mg Injection, powder, lyophilized, for solution Intravenous 7 mg/1mL Powder, for solution Intravenous 268 mg / vial Powder, for solution Intravenous 7 mg/1mL Powder Intravenous 350 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at June 13, 2005 13:24 / Updated at April 30, 2021 13:05